By Chris Woolston CONSUMER HEALTH INTERACTIVEBelow: • Coping with Alzheimer's • Medical science fights back
Alzheimer's disease is like a cat burglar. It slips into a person's life without making a sound, and soon treasured possessions start disappearing: memory, personality, independence. For many years, even the top medical detectives in the country were baffled by such robbery. Doctors knew that Alzheimer's filled a person's brain with tangled strings of protein and sticky clumps of plaque, but nobody had a clue where this clutter came from. Worse, nobody knew how to help the victims. In the bad old days -- which weren't that long ago -- people with Alzheimer's were often locked away in asylums and controlled with heavy sedatives. Alzheimer's is still a dreadful, devastating condition, but the outlook for patients and their families is brighter than before. Thanks to a new understanding of the emotions and needs of Alzheimer's patients, families can call on many tried-and-true techniques for keeping loved ones comfortable. With support, most patients can face the disease for many years before having to move to a nursing home; some are able to remain with their families to the end. Recent medical breakthroughs offer even more cause for hope. Researchers are beginning to understand exactly how Alzheimer's kills brain cells, and every new insight brings them closer to finding a cure for the terrifying affliction. Their work has already brought a payoff: Doctors can now prescribe drugs to slow down the disease, and large-scale studies are putting promising new treatments to the test. Scientists are looking at everything from antioxidants, estrogen, anti-inflammatory drugs, cholesterol-lowering drugs, and nerve-growth factors as possible elements in protecting against the disease. Indeed, the need for a cure has never been greater. As many as 5.3 million Americans suffer from Alzheimer's, and that toll could grow dramatically as the nation ages. If it can't be stopped, between 11 and 16 million people over age 65 are expected to be living with the disease in 2050. Bill Thies, the Alzheimer's Association's vice president of medical and scientific affairs, puts it this way: "What we are facing is an epidemic of major proportions." Currently, it's impossible to say who will develop Alzheimer's and who will be spared. Some people inherit genes that make them vulnerable to the disease. People who have a parent, brother or sister with the disease are more likely to develop Alzheimer’s. Other possible risk factors include serious head injury and conditions that damage the heart or blood vessels (like heart disease, stroke, diabetes, high blood pressure and high cholesterol). Coping with Alzheimer's The first step to coping with Alzheimer's disease is knowing what to expect. Every case is different, but the disease tends to follow a predictable downward spiral. In the first stage, which may last two to four years, Alzheimer's is subtle and easily overlooked. In the beginning, people may have trouble coming up with the names of acquaintances or of common objects such as bread or sugar. They may put keys or an iron in odd places, like the refrigerator, and be unable to remember how they got there. Friends and relatives may notice small changes in mood, perhaps a loss of interest in favorite activities or unusually high levels of anxiety. Later, the disease will start interfering with everyday life. People may start losing things and making unusual mistakes at home or on the job. Pretty soon, undone chores, unpaid bills, and missed appointments start to pile up. The patient may notice a problem, but he or she will probably deny anything is wrong. In the middle stage of the disease -- which may go on seven or more years -- memory loss and confusion begin to take over. Patients may begin to have trouble recognizing family members or remembering events of the day before. They may ask the same question over and over again, never quite registering the answer. They may wander the house in the middle of the night, perhaps calling for a parent who died decades ago. Simple chores like cooking, washing clothes, and even bathing become impossible. Many patients eventually lose control over bladder and bowels during this stage. In the last stage of Alzheimer's, patients lose all touch with reality. They may not recognize anybody at all, or even their own face in the mirror. They will need help for even the simplest tasks, such as combing their hair. Eventually, they will be unable to walk or talk. The average lifespan for someone with Alzheimer's is 8 years from the time symptoms first appear, though some people may live up to 20 years with the disease. Even in this stage, however, Alzheimer's patients still respond to kindness and love. "Before AD, my husband was too macho to submit willingly to his sons' physical affection," writes Lela Knox Shanks in her memoir Your Name Is Hughes Hannibal Shanks: A Caregiver's Guide to Alzheimer's. "Now he is more accepting; he smiles and obviously enjoys the touching and affection... Clearly, a loss of cognition is not a loss of one's feelings or one's humanity." Medical science fights back At every stage, Alzheimer's poses enormous challenges to family members. And at every stage, family members can meet those challenges with patience and compassion. Many excellent resources, including the national Alzheimer's Association, caregiver support groups, and books such as Alzheimer's: A Caregiver's Guide and Sourcebook, At the Heart of Alzheimer's, and The 36-Hour Day, help caregivers understand the disease and support their loved ones. As Alzheimer's progresses, a caring family physician will be an invaluable ally. First, he or she can determine if the diagnosis is more likely to be Alzheimer's rather than some of the other conditions that cause dementia or dementia-like symptoms. In addition to providing advice and guidance, he or she can prescribe medications to slow down a patient's decline or ease his depression or anxiety. For instance, cholinesterase inhibitors prevent the breakdown of a chemical messenger important to learning and memory. On average, about half the patients who take these medications are able to delay the worsening of symptoms for 6 to 12 months. The most commonly prescribed cholinesterase inhibitors are galantamine (Razadyne), donepezil (Aricept), and rivastigmine (Exelon). For patients with moderate to severe Alzheimer's, the drug memantine (Namenda), approved by the FDA in 2003, is the first drug shown to slow progression of the disease in advanced-stage patients. Doctors also prescribe Aricept for the treatment of moderate to severe Alzheimer's. These drugs don't work for all people, however, and they can cause significant side effects. They require monitoring by a physician. Unfortunately, even the modest improvements brought on by drugs don't last, and in most cases Alzheimer's eventually continues its relentless march. In the future, patients and their families may be able to buy precious time with products already in their medicine cabinet. Recent studies have suggested that large amounts of vitamin E and regular doses of common nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin, ibuprofen, or naproxen may help protect the brain and slow the course of Alzheimer's. Some small studies have found that ginkgo biloba can slow the course of early-stage Alzheimer's, but a major study published in the Journal of the American Medical Association in 2008 found no effect among elderly people with mild cognitive impairment. The studies on NSAIDs and other possible treatments are not definitive, and the optimism with which these findings were announced has faded considerably. Moreover, these treatments carry risks -- large doses of vitamin E thin the blood and can lead to serious bleeding; common NSAIDS can cause ulcers and other complications; and ginkgo can clash with blood-thinning medication. So the message is clear -- don't try any therapy without your doctor's supervision. All of these therapies are important advances -- and they may one day seem as crude as the overuse of medicinal leeches. New discoveries are constantly fueling the hope that Alzheimer's will soon become as treatable as hypertension or diabetes. Researchers are learning more about the changes that occur in the brain of an Alzheimer's patient using brain imaging technology like magnetic resonance imaging (MRI) and positron emission tomography (PET). These techniques, along with certain biological markers and highly developed tests of memory and language skills, may help investigators identify people at risk for Alzheimer's. They may also make it easier for doctors to identify how well different treatments are working. As researchers continue to unravel the different genes, proteins, and enzymes that drive Alzheimer's, talk of a cure no longer seems too far-fetched. For now, nobody knows how or when Alzheimer's will finally be defeated. But one thing is certain: Such a victory can never come too soon. -- Chris Woolston, M.S., is a health and medical writer with a master's degree in biology. He is a contributing editor at Consumer Health Interactive, and was a staff writer at Hippocrates, a magazine for physicians. He has also covered science issues for Time Inc. Health, WebMD, and the Chronicle of Higher Education. His reporting on occupational health earned him an award from the Northern California Society of Professional Journalists.
Further Resources Alzheimer's Association This Web site has resources for people living with Alzheimer's, their caregivers, and professionals who want to keep up with the latest medical advances. Family Caregiver Alliance This site has information on services, research, and education for those caring for loved ones with chronic health conditions.
References Sloane, Philip. Advances in the Treatment of Alzheimer's Disease. American Family Physician. November 1, 1998: Vol. 58, No. 6, 1577-1586.
Arkin, Sharon. Elder Rehab: A Student-Supervised Exercise Program for Alzheimer's Patients. The Gerontologist. 1999:Vol. 39, No. 6, 729-735.
Virginia Bell and David Troxel. The Best Friends Approach to Alzheimer's Care. Health Professions Pr: 1996. 264 pp.
Dr. William Molloy and Dr. Paul Caldwell. Alzheimer's Disease: Everything you Need to Know. Firefly Books. 1998, 208 pp.
Michael Castleman et al. There's Still a Person in There: The Complete Guide to Treating and Coping with Alzheimer's. Putnam Publishers, 2000.
Howard Gruetzner, M.Ed. A Caregiver's Guide and Sourcebook. John Wiley &Sons, 1992.
Nancy L. Mace, M.A., and Peter V. Rabins, M.D., M.P.H. The 36-Hour Day. Johns Hopkins University Press, 1999.
Lela Knox Shanks. Your Name Is Hughes Hannibal Shanks: A Caregiver's Guide to Alzheimer's. The Penguin Group, 1999.
Carol Simpson. At the Heart of Alzheimer's. Manor HealthCare Corporation, 1996.
Progress Report on Alzheimer's Disease. New Discoveries, New Insights. U.S. Department of Health and Human Services.
Alzheimer's Disease Fact Sheet. Alzheimer's Association. 2006.
Alzheimer's Disease: Frequently Asked Questions, NIH Senior Health. Last reviewed January 14, 2005.
National Institute on Aging. Alzheimer's Disease: Unraveling the Mystery. The Search for New Treatments. http://www.nia.nih.gov/Alzheimers/Publications/UnravelingTheMystery/Part2/subpage03.htm
DeKosky, ST, et al. Ginkgo biloba for prevention of dementia: A randomized controlled trial. JAMA. 2008 Nov 19; 300(19): 2253-62.
Alzheimer’s Association. 2009 Alzheimer’s disease facts and figures. Alzheimer’s and Dementia. May 2009; 5(3).
Alzheimer’s Association. Risk factors. July 2008.
National Institute on Aging. Alzheimer's Disease Medications Fact Sheet. February 2009. http://www.nia.nih.gov/Alzheimers/Publications/medicationsfs.htm
Reviewed by Patrick Irvine, MD, a noted geriatrician and pharmacologist who lives in Minneapolis, MN.
Last updated July 9, 2009
Copyright © 2000 Consumer Health Interactive
|